Skip to main content

    ReST Committee Update on Inflammation After Intravitreal Injections

    ASRS 2023

    Drs. Ajay Kuriyan and Andre Witkin discuss updates given at ASRS 2023 on the rare but serious intraocular inflammatory side effects recently reported after the use of Syfovre. Syfovre, which was approved in early 2023, is the first and only treatment option shown to slow the progression of geographic atrophy. However, its use has been associated with multiple reports of severe vision-threatening events, including several cases of occlusive vasculitis and neovascular glaucoma. Dr. Witkins provides an overview of what the ASRS Research and Safety in Therapeutics (ReST) Committee knows so far about these events and what this may mean for current and future patients with geographic atrophy.

    Financial Disclosures: Dr. Ajay Kuriyan discloses financial relationships with Adverum, Annexon, National Eye Institute (Grant Support); Alimera Sciences, Allergan, Bausch + Lomb, EyePoint Pharmaceuticals, Novartis, Alcon Pharmaceuticals (Consultant/Advisor); Optos (Lecture Fees/Speakers Bureau); Lumata Health, Recens Medical (Consultant/Advisor, Private Equity/Stock Holder); Spark Therapeutics (Consultant/Advisor, Lecture Fees/Speakers Bureau); Genentech (Consultant/Advisor, Lecture Fees/Speakers Bureau, Grant Support). Dr. Andre Witkin discloses financial relationships with Apellis and Genentech (Grant Support).